Monopar Therapeutics
MNPRNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MNPR. That does not mean none is planned.
Get an email about MNPR's next catalysts
Track Monopar Therapeutics (MNPR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming events in our data (conference, earnings).See the timeline
2 upcoming, 0 past
Conference — ALXN1840
For Wilson disease. Monopar Therapeutics appointed Jeffrey D. Kent, M.D. as Executive Vice President of Medical Affairs and announced two ALXN1840 presentations at AASLD – The Liver Meeting® 2026 in November.
SourceMNPR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.86 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
No drugs found in this phase.
Frequently asked questions
When is Monopar Therapeutics's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Monopar Therapeutics (MNPR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MNPR biotech catalysts?→
Add MNPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Monopar Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.